Join Gritstone bio (Nasdaq: GRTS) for a virtual KOL event featuring J. Randolph Hecht, MD, (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) who will discuss the unmet need and current treatment landscape for patients with metastatic microsatellite stable colorectal cancer (MSS-CRC).

The event will also highlight the development of Gritstone’s personalized neoantigen vaccine program, GRANITE, as a potential treatment for immunologically “cold” tumors, including MSS-CRC. Mature progression-free survival data from a randomized Phase 2 study of GRANITE in frontline MSS-CRC are expected in the third quarter of 2024.

A live Q&A session will follow the formal presentations.